Welcome to our dedicated page for Nanobiotix S.A. American Depositary Shares news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. American Depositary Shares stock.
Nanobiotix S.A. (Euronext: NANO / ISIN: FR0011341205) is a leading clinical-stage nanomedicine company specializing in the development of groundbreaking approaches for cancer treatment. The company's core technology, NanoXray, augments the effectiveness of radiotherapy, offering a more efficient treatment option for cancer patients. The innovative NanoXray products are designed to be compatible with existing radiotherapy treatments and aim to treat a broad spectrum of solid tumors, such as soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma.
The primary product candidate, NBTXR3, is currently undergoing evaluation for its efficacy in treating soft tissue sarcoma, head and neck cancers, prostate cancer, and liver cancers (both primary and metastases). Additionally, Nanobiotix has partnered with PharmaEngine in Taiwan to conduct trials for head and neck cancer and rectal cancer in the Asia Pacific region.
Nanobiotix has also embarked on a preclinical research program in immuno-oncology, further expanding its portfolio and potential for transformative cancer therapies. NBTXR3 works by magnifying the effects of radiotherapy within tumor cells, thereby enhancing cancer treatment without increasing the dose to surrounding healthy tissues.
Recently, Nanobiotix has been focused on validating the safety and efficacy of RT-activated NBTXR3 by moving to global registration for LA-HNSCC, accounting for the majority of its operational and financial resources. The company plans to provide an updated global development plan for NBTXR3 after further alignment with the Joint Steering Committee (JSC).
In terms of financial performance, Nanobiotix has laid out a cautious strategy, ensuring that it remains well-funded to support ongoing and future operations. Their forward-looking statements highlight the potential risks and uncertainties that could affect their business and financial performance.
For the latest updates, Nanobiotix has scheduled a conference call and webcast on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST. It continues to engage the market, providing transparency to shareholders through various media and regular updates on their progress and milestones.
To keep up with the latest news, visit www.nanobiotix.com.
Nanobiotix, a company listed on Euronext Paris and Nasdaq, has released its monthly report on voting rights and shares capital as of July 31, 2024. The report, in compliance with French regulatory requirements, reveals the following key figures:
• Number of Shares Outstanding: 47,426,851
• Total Theoretical Voting Rights: 49,200,912
• Total Exercisable Voting Rights: 49,178,794
This disclosure is part of Nanobiotix's commitment to transparency and adherence to French financial regulations. The company trades under the ticker NBTX on Nasdaq and is part of Euronext Paris Compartment B.
Nanobiotix has disclosed its voting rights and share capital details as of June 30, 2024. The company has 47,426,851 shares outstanding and 49,198,624 total voting rights, with 49,176,506 voting rights exercisable. This disclosure aligns with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority. Nanobiotix will continue to publish monthly updates if there are changes in the voting rights and shares comprising its capital.
NANOBIOTIX (NASDAQ: NBTX), a late-clinical stage biotech company, will host a virtual KOL event on June 18, 2024, from 9:00-10:30AM EDT / 3:00-4:30PM CEST. The event will feature experts including Dr Colette Shen, Dr Ari Rosenberg, and Dr Jeffrey Bockman, who will discuss the company's lead product, NBTXR3. This product, when combined with immunotherapy, has shown promising results in controlling disease and tumor response in head and neck cancer patients. Detailed insights from the 2024 ASCO Annual Meeting will be reviewed, highlighting NBTXR3's mechanisms, patient treatment responses, and its potential role in addressing unmet medical needs in recurrent or metastatic head and neck cancer. Registration for the event is available online, and it will be replayed and archived on the company's website.
On June 11, 2024, Nanobiotix announced its updated voting rights and share capital, as per the requirements of the French Commercial Code and the French Financial Markets Authority. As of May 31, 2024, the company has 47,133,328 shares outstanding and a total of 48,904,378 voting rights. The theoretical total voting rights stand at 48,882,260. Nanobiotix will continue to publish monthly updates on its voting rights and share capital if there are changes in the figures previously disclosed.
Nanobiotix announced new data from Study 1100, showing disease control and tumor response in patients treated with RT-activated NBTXR3 followed by anti-PD-1 therapy for second-line or later recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). The study involved 68 heavily pre-treated patients. Results indicated a 48% overall response rate (ORR) and 76% disease control rate (DCR) in anti-PD-1 naïve patients, and a 28% ORR and 68% DCR in anti-PD-1 resistant patients. For the naïve patients, median progression-free survival (mPFS) was 7.3 months, and median overall survival (mOS) was 26.2 months. For resistant patients, mPFS was 4.2 months, and mOS was 7.8 months. The treatment showed favorable safety and feasibility, with serious Grade 3+ adverse events occurring in 8.8% of patients. These promising early efficacy signals were presented at ASCO 2024, and Nanobiotix plans further exploration in randomized trials.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX) has announced the presentation of new data from its US Phase 1 Study 1100 at the 2024 Annual Meeting of the American Society for Clinical Oncology (ASCO). The study evaluates NBTXR3 combined with anti-PD-1 therapy in patients with recurrent or metastatic head and neck cancer. Coordinating Investigator Colette Shen, MD, PhD, will present early efficacy signs, involving 68 patients (33 anti-PD-1 naive and 35 anti-PD-1 resistant). Following the ASCO presentation on June 2nd, 2024, Nanobiotix will host an investor conference call. The data from the dose escalation part and the ongoing expansion part demonstrate promising early results, particularly in a challenging patient population.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX), a biotechnology company in its late-clinical stage, is set to participate in the Jefferies Global Healthcare Conference. This event is scheduled for June 5, 2024, at 5:00 PM EDT in New York, NY. Bart Van Rhijn, the CFO of Nanobiotix, will be leading a fireside chat that will be webcast live on the company's website. The webcast will also be available for replay post-event.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotech company, released its Q1 2024 operational and financial update on May 22, 2024. The company reported cash and cash equivalents of €58.9 million as of March 31, 2024, which, along with a $20 million milestone payment, is projected to fund operations into Q3 2025. NANOBIOTIX will hold a conference call and webcast to discuss these updates and take questions. The CEO, Laurent Levy, will lead the session.
Nanobiotix has announced significant progress in its global collaboration with Janssen to develop and commercialize its radioenhancer NBTXR3. This collaboration aims to expand the application of NBTXR3 in treating cancer patients who undergo radiotherapy. Key updates include the removal of a planned futility analysis for the ongoing Phase 3 head and neck cancer trial, with interim analysis results expected in 1H2026. Additionally, the company received FDA approval to proceed with a new Phase 2 study for lung cancer. These advancements are part of a broader strategy to leverage NBTXR3’s potential to fund the development of other nanoparticle-based therapies. Nanobiotix is also aligning with Janssen on global manufacturing and operational strategies, including a transfer of trial sponsorship to Janssen and a focus on expanding indications beyond head and neck and lung cancer.
Nanobiotix has disclosed updated information on its share capital and voting rights in compliance with French regulations. As of April 30, 2024, the company has 47,133,328 outstanding shares. The total number of theoretical voting rights is 48,903,298, while exercisable voting rights stand at 48,881,180. This update follows Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority. Nanobiotix will continue to publish monthly updates if there are changes in these figures.
FAQ
What is the current stock price of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is the market cap of Nanobiotix S.A. American Depositary Shares (NBTX)?
What is Nanobiotix S.A. known for?
What is NanoXray technology?
What types of cancer does NBTXR3 target?
Who is Nanobiotix partnered with in the Asia Pacific region?
What recent projects are Nanobiotix involved in?
When is the next conference call and webcast scheduled?
How does NBTXR3 enhance radiotherapy?
What is the significance of Nanobiotix’s preclinical research program?
Where can I find more information about Nanobiotix?
